Biospecimens and Biorepositories: From Afterthought to Science

Biospecimens are recognized as critical components of biomedical research, from basic studies to clinical trials and epidemiologic investigations. Biorepositories have existed in various forms for more than 150 years, from early small collections in pathology laboratories to modern automated facilities managing millions of samples. As collaborative science has developed, it has been recognized that biospecimens must be of consistent quality. Recent years have seen a proliferation of best practices and the recognition of the field of “biospecimen science.” The future of this field will depend on the development of more evidence-based practices in both the research and clinical settings. As the field matures, educating a new generation of biospecimen/biobanking scientists will be an important need. Cancer Epidemiol Biomarkers Prev; 21(2); 253–5. ©2012 AACR.

[1]  L. Zhao,et al.  Simultaneous isolation of DNA and RNA from the same cell population obtained by laser capture microdissection for genome and transcriptome profiling. , 2008, The Journal of molecular diagnostics : JMD.

[2]  T. Hudson,et al.  The art and science of biobanking , 2011, Human Genetics.

[3]  Elisa Eiseman,et al.  Handbook of human tissue sources : a national resource of human tissue samples , 1999 .

[4]  John Shon,et al.  A DNA-Based Biological Sample Tracking Method , 2005 .

[5]  Peter Kuhn,et al.  Cytomorphology of Circulating Colorectal Tumor Cells:A Small Case Series , 2010, Journal of oncology.

[6]  Philip M Baird,et al.  Large-Scale Repository Design , 2005 .

[7]  M. García-Closas,et al.  Molecular Pathology in Epidemiologic Studies: A Primer on Key Considerations , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[8]  S. Chanock,et al.  Genome-wide association studies and "the art of the soluble". , 2010, Journal of the National Cancer Institute.

[9]  P. Elliott,et al.  The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. , 2008, International journal of epidemiology.

[10]  M. Salgaller.  American Association for Cancer Research , 2000, Expert opinion on investigational drugs.

[11]  Jim Vaught,et al.  A review of international biobanks and networks: success factors and key benchmarks. , 2009, Biopreservation and biobanking.

[12]  Kurt Zatloukal,et al.  Proteomic analysis of PAXgene-fixed tissues. , 2010, Journal of proteome research.

[13]  M. Brown,et al.  Saliva-Derived DNA Performs Well in Large-Scale, High-Density Single-Nucleotide Polymorphism Microarray Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[14]  Helen M. Moore,et al.  International Approaches to Advancing Biospecimen Science , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[15]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[16]  A. Hsing,et al.  Limitations of Direct Immunoassays for Measuring Circulating Estradiol Levels in Postmenopausal Women and Men in Epidemiologic Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[17]  M C Kline,et al.  Optimizing Storage and Handling of DNA Extracts. , 2010, Forensic science review.

[18]  Peter Medawar,et al.  The art of the soluble , 2021, Nature.

[19]  D. Ransohoff,et al.  Sources of bias in specimens for research about molecular markers for cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Vaught,et al.  International Efforts to Develop Biospecimen Best Practices , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[21]  L. Pusztai,et al.  Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. , 2011, Journal of the National Cancer Institute.